Amneal Pharmaceuticals, Inc. (AMRX) FY2025 10-K Annual Report
Amneal Pharmaceuticals, Inc. (AMRX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Amneal Pharmaceuticals, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of complex generic and branded pharmaceutical products focusing on high-barrier, high-value formulations
- • New product emphasis: Launch of five oncology biosimilars including Boncresa™ and Oziltus™ FDA-approved in Dec 2025, plus first complex inhalation aerosol generics from Ireland facility
Management Discussion & Analysis
- • Net cash from operating activities $340.0M in 2025 vs $295.1M in 2024; 15.2% increase but lower YoY excluding $52.4M prior litigation settlement
- • Net cash used in investing activities $112.3M in 2025 vs $63.0M in 2024; 78.2% increase due to higher capex and property deposits
Risk Factors
- • Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754
- • Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text
Amneal Pharmaceuticals, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$3.0B
▲ +8.0% YoY
Net Income
$72M
▲ +161.6% YoY
Gross Margin
36.9%
▲ +36bp YoY
Operating Margin
13.1%
▲ +413bp YoY
Net Margin
2.4%
▲ +657bp YoY
ROE
-101.8%
▼ -20876bp YoY
Total Assets
$3.7B
▲ +5.1% YoY
EPS (Diluted)
$0.22
▲ +157.9% YoY
Operating Cash Flow
$340M
▲ +15.2% YoY
Source: XBRL data from Amneal Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amneal Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.